Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study

Fineline Cube Sep 7, 2023

Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...

Company Policy / Regulatory

FDA Addresses Looming Migraine Treatment Shortage with Tonix Pharmaceuticals Commitment

Fineline Cube Sep 7, 2023

The US Food and Drug Administration (FDA) is actively engaging with pharmaceutical companies to address...

Company Drug

Henan Zhongshuai’s Dexmethylphenidate Hydrochloride Capsules Target Priority Review for Pediatric ADHD

Fineline Cube Sep 7, 2023

Henan Zhongshuai Pharmaceutical Co., Ltd., a China-based pharmaceutical company, is poised to secure priority review...

Company Drug

Amneal Pharmaceuticals Receives China Approval for Sevelamer Carbonate

Fineline Cube Sep 7, 2023

US-based Amneal Pharmaceuticals Inc. (NYSE: AMRX) has announced that it has received approval from the...

Company Drug

CSPC Pharmaceutical’s Narlumosbart Approved by NMPA for Bone Giant Cell Tumors

Fineline Cube Sep 7, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, Shanghai JMT Biotechnology Co.,...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for CDE’s BTD Status

Fineline Cube Sep 7, 2023

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its HER2 targeted antibody-drug...

Policy / Regulatory

NMPA Drafts Guidelines for Supervising Online Drug Exchange Platforms

Fineline Cube Sep 7, 2023

The National Medical Products Administration (NMPA) has released draft “Online Third-party Drug Exchange Platforms Inspection...

Company Drug

Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris

Fineline Cube Sep 7, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...

Company Deals

uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy

Fineline Cube Sep 7, 2023

China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell...

Policy / Regulatory

CDE’s 2022 Drug Review Report: A Year of Pandemic Response and Regulatory Milestones

Fineline Cube Sep 7, 2023

The Center for Drug Evaluation (CDE) has released its comprehensive 2022 annual drug review report,...

Company Drug

Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist

Fineline Cube Sep 7, 2023

China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical...

Company Deals

Sino Medical Sciences Technology to Acquire Majority Stake in US Endovascular Device Firm eLum

Fineline Cube Sep 7, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced plans to acquire a 72.73%...

Company Medical Device

Acotec Scientific Holdings Receives Marketing Approvals for Vericor-14 Microcatheter in Japan and Thailand

Fineline Cube Sep 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approvals...

Company Drug

Brii Biosciences Announces Positive Interim Data for BRII-179 Vaccine in Chronic Hepatitis B

Fineline Cube Sep 7, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from...

Company Drug

MSD’s Gardasil 9 HPV Vaccine Demonstrates 10-Year Efficacy in Adolescents

Fineline Cube Sep 6, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant...

Company Deals

Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer

Fineline Cube Sep 6, 2023

China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined...

Company Deals

Abbott to Acquire Insulin Management Firm Bigfoot Biomedical

Fineline Cube Sep 6, 2023

Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...

Policy / Regulatory

Taizhou Port Designated as Drug Import Port by NMPA and General Administration of Customs

Fineline Cube Sep 6, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have released a...

Company

Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms

Fineline Cube Sep 6, 2023

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...

Policy / Regulatory

Li Li Appointed as New Director of NMPA

Fineline Cube Sep 6, 2023

The State Council has released an announcement regarding appointments and dismissals within the government. Among...

Posts pagination

1 … 530 531 532 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.